Volume 29, Number 7—July 2023
Research Letter
Long-Term SARS-CoV-2 Antibody Seroprevalence in Blood Donors, Italy
Table
Univariate analysis |
Multivariate analysis |
||||
---|---|---|---|---|---|
Variable | OR (95% CI) | p value | OR (95% CI) | p value | |
Age | 0.985 (0.973–0.996) | 0.008 | 0.984 (0.964–1.005) | 0.135 | |
Sex | 1.047 (0.755–1.453) | 0.783 | |||
Body mass index | 1.001 (1.000–1.002) | 0.178 | |||
Smoking |
0.498 (0.193–1.287) |
0.150 |
|||
Concurrent conditions | 0.600 (0.299–1.205) | 0.151 | |||
Allergic rhinitis | 0.180 (0.043–0.757) | 0.019 | 0.170 (0.40-0.719) | 0.016 | |
ACE inhibitor use |
0.181 (0.089–0.365) |
<0.011 |
1.036 (0.452–2.373) |
0.933 |
|
Chronic therapies | 0.793 (0.392–1.6020) | 0.517 | |||
Influenza vaccination | 0.678 (0.276–1.666) | 0.397 | |||
Family case of SARS-CoV-2 infection | 0.938 (0.407–2.159) | 0.880 | |||
Education level | 1.248 (0.824–1.892) | 0.296 | |||
Municipality of residence | 1.011 (0.996–1.027) | 0.134 |
*Bold text indicates significance. ACE, angiotensin-converting enzyme.
Page created: April 26, 2023
Page updated: June 21, 2023
Page reviewed: June 21, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.